Drug Trial Radar · NCT00634660
Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria
Last checked: Nov 20, 2026Latest source record: Feb 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
May 2008
Primary completion
Apr 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Mar 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of injections of rAvPAL-PEG in subjects with PKU.
Conditions
- Phenylketonuria
Interventions
rAvPAL-PEGDrug
rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
Primary outcomes
What the sponsor says the trial is designed to measure.
- • To assess the incidence of treatment-emergent adverse events of a single, subcutaneous (SC) injections of rAvPAL-PEG in subjects with PKU.Time frame: 6 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Children's Memorial Hospital
Chicago, Illinois
University of Minnesota Medical Center-Fairview
Minneapolis, Minnesota
Washington University Center for Applied Research Sciences
St Louis, Missouri
Mount Sinai Medical Center
New York, New York
Oregon Health & Science University
Portland, Oregon
University of Pittsburgh
Pittsburgh, Pennsylvania
University of Utah Hospital
Salt Lake City, Utah
University of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.